Implementation of a Tumor Response Assessment Program Integrating the Shared Medical Decision Into the Organ Preservation Strategy for Rectal Cancer Patients

Not Applicable

Recruiting

• Conditions: Rectal Cancer

• Registration Number: NCT06740357
• Lead Sponsor: Centre Hospitalier Universitaire Dijon

Brief Summary

The adoption of total mesorectal excision (TME) has standardized rectal cancer surgery and improved oncological outcomes. In locally advanced rectal cancer, neoadjuvant radio chemotherapy (NACRT) has further improved oncological benefit. Although these strategies result in good 5-year disease-free survival rates, they are associated with significant morbidity, in particular permanent long-term bowel, urinary and sexual dysfunction. In rectal cancer management, the main objective of organ preservation is to avoid or reduce morbidity and impact on quality of life after rectal resection, without compromising oncological outcomes.

The aim of this project is to evaluate the efficacy of a defined response monitoring program, including a shared decision process, as a strategy for assessing tumor response in locally advanced rectal cancer after neoadjuvant therapy.

This is a national, phase III, randomized, open-label, multicenter clinical trial comparing the tumor response monitoring program with shared decision-making, versus standard tumor response assessment in organ preservation strategies in rectal cancer.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-12-10
• Study First Submitted: 2024-12-13
• Study First Submitted QC: 2024-12-17
• Study First Posted: 2024-12-18
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-08
• Last Update Posted: 2025-04-09
• Primary Completion: 2031-03
• Study Completion: 2031-03

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 270

Inclusion Criteria

• Patient aged 18 to 80

• Histologically proven lieberkuhnian adenocarcinoma with MSS status ;

• Patient who has or is due to receive neoadjuvant treatment (4 to 6 courses of (m)FOLFIRINOX or FOLFOX chemotherapy + CAP 50 radiochemotherapy or CAP 50 radiochemotherapy alone);

• BEFORE any neoadjuvant treatment:

  • Tumor classified T2T3 (on MRI)

  • N0-N1 (≤ 3 positive lymph nodes * or size ≤ 8 mm) (on MRI)

  • * positive node = node size > 5 mm minor axis and/or morphologically suspicious appearance Tumor size ≤4 cm (ON MRI)

  • No distant metastasis (M0)_ TAP scan or PET scan

  • ≤ 8 cm from anal margin (On MRI) (Clinical examination*)

    *if the clinical examination is not possible, then the source data is that of the MRI.

  • No invasion of the anal canal and/or sphincters (internal and external) (On MRI)

• Operable patient

• Ability to comply with the protocol and follow-up appointments (repeated assessment consultations and close follow-up if randomized to the Experimental Group);

• Person affiliated with or benefiting from a social security scheme;

• Free and informed consent signed by the patient.

Exclusion Criteria

• Patients with a history of chemotherapy or pelvic irradiation (excluding neoadjuvant treatment)
• Contraindication to pelvic MRI
• Patients with MSI status undergoing immunotherapy
• Other concomitant cancer or history of cancer within 5 years, with the exception of carcinoma in situ of the cervix or basal cell or squamous cell skin carcinoma or any other carcinoma in situ, considered cured
• Women who are pregnant, likely to become pregnant, or who are breast-feeding;
• Person under guardianship, curatorship or safeguard of justice, or person deprived of liberty.
• Unable to undergo medical follow-up for geographical, social or psychological reasons.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Organ preservation rate	2 years after the start of neoadjuvant treatment	An organ-preserving patient is defined as a patient who has not undergone rectal resection.

Trial Locations

Locations (1)

CHU Dijon Bourgogne; 🇫🇷 Dijon, France